Taurochenodeoxycholic AcidCAS# 516-35-8 |
- Tauroursodeoxycholic acid
Catalog No.:BCN6953
CAS No.:14605-22-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 516-35-8 | SDF | Download SDF |
| PubChem ID | 387316 | Appearance | White crystal |
| Formula | C26H45NO6S | M.Wt | 499.7 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | 12-Deoxycholyltaurine | ||
| Solubility | DMSO : ≥ 25 mg/mL (50.03 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid | ||
| SMILES | CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C | ||
| Standard InChIKey | BHTRKEVKTKCXOH-BJLOMENOSA-N | ||
| Standard InChI | InChI=1S/C26H45NO6S/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-22,24,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16-,17+,18-,19-,20+,21+,22-,24+,25+,26-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Taurochenodeoxycholic Acid Dilution Calculator
Taurochenodeoxycholic Acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0012 mL | 10.006 mL | 20.012 mL | 40.024 mL | 50.03 mL |
| 5 mM | 0.4002 mL | 2.0012 mL | 4.0024 mL | 8.0048 mL | 10.006 mL |
| 10 mM | 0.2001 mL | 1.0006 mL | 2.0012 mL | 4.0024 mL | 5.003 mL |
| 50 mM | 0.04 mL | 0.2001 mL | 0.4002 mL | 0.8005 mL | 1.0006 mL |
| 100 mM | 0.02 mL | 0.1001 mL | 0.2001 mL | 0.4002 mL | 0.5003 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Taurochenodeoxycholic acid is one of the main bioactive substances of animals' bile acid.
In Vitro:Studies have suggested that taurochenodeoxycholic acid as a signaling molecule shows obvious anti-inflammatory and immune regulation properties. Taurochenodeoxycholic acid dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, PKC mRNA levels and activities are significantly augmented by taurochenodeoxycholic acid treatments. In addition, JNK, caspase-3 and caspase-8 mRNA expression levels and activities are increased by taurochenodeoxycholic acid[1].
In Vivo:Taurochenodeoxycholic acid in dosages of 0.05 and 0.1g/kg can decrease the pulmonary coefficient in the model mice, taurochenodeoxycholic acid in dosages of 0.05 and 0.1g/kg reduce the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice, the expression level of MMP-9 increases, while it has no significant effects on MMP2[2]. Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation[3]. Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats[4].
References:
[1]. Wang X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway. Eur J Pharmacol. 2016 Sep 5;786:109-15.
[2]. Zhou C, et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak J Pharm Sci. 2013 Jul;26(4):761-5.
[3]. Uchida A, et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol. 1997 May;272(5 Pt 1):G1249-57.
[4]. Liu M, et al. Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. Int Immunopharmacol. 2011 Dec;11(12):2150-8.
- Methylmalonate
Catalog No.:BCC7986
CAS No.:516-05-2
- Cuspidiol
Catalog No.:BCN3942
CAS No.:51593-96-5
- DMH4
Catalog No.:BCC6196
CAS No.:515880-75-8
- Neoechinulin A
Catalog No.:BCN5638
CAS No.:51551-29-2
- Flurizan
Catalog No.:BCC2342
CAS No.:51543-40-9
- Vitexin argininate
Catalog No.:BCC8179
CAS No.:51542-56-4
- GW 803430
Catalog No.:BCC7897
CAS No.:515141-51-2
- Adiantulupanone
Catalog No.:BCN7360
CAS No.:51511-05-8
- Cochinchinenin A
Catalog No.:BCN3496
CAS No.:221696-69-1
- (+)-Turicine
Catalog No.:BCC8361
CAS No.:515-24-2
- Sclareol
Catalog No.:BCN2395
CAS No.:515-03-7
- H-Tyr(tBu)-OMe.HCl
Catalog No.:BCC2672
CAS No.:51482-39-4
- Cerevisterol
Catalog No.:BCN5640
CAS No.:516-37-0
- Allopregnanolone
Catalog No.:BCC7737
CAS No.:516-54-1
- 20(S)-Hydroxycholesterol
Catalog No.:BCC7937
CAS No.:516-72-3
- Z-D-Glu(OtBu)-OH
Catalog No.:BCC2771
CAS No.:51644-83-8
- BML-277
Catalog No.:BCC4245
CAS No.:516480-79-8
- Murrangatin diacetate
Catalog No.:BCN5641
CAS No.:51650-59-0
- 2-Methoxyphenalen-1-one
Catalog No.:BCN7181
CAS No.:51652-39-2
- Erythrartine
Catalog No.:BCN5642
CAS No.:51666-26-3
- Kadsurin
Catalog No.:BCN3634
CAS No.:51670-40-7
- 2-Acetylbutyrolactone
Catalog No.:BCC8515
CAS No.:517-23-7
- Hematoxylin
Catalog No.:BCC5322
CAS No.:517-28-2
- Sennidin B
Catalog No.:BCN6355
CAS No.:517-44-2
Simultaneous determination of nine kinds of dominating bile acids in various snake bile by ultrahigh-performance liquid chromatography with triple quadrupole linear iontrap mass spectrometry.[Pubmed:29129604]
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:245-252.
Snake bile is one of the most expensive traditional Chinese medicines (TCMs). However, due to the complicated constitutes of snake bile and the poor ultraviolet absorbance of some trace bile acids (BAs), effective analysis methods for snake bile acids were still unavailable, making it difficult to solve adulteration problems. In present study, ultrahigh-performance liquid chromatography with triple quadrupole linear ion trap mass spectrometry (UHPLC-QqQ-MS/MS) was applied to conduct a quantitative analysis on snake BAs. The mass spectrometer was monitored in the negative ion mode, and multiple-reaction monitoring (MRM) program was used to determine the contents of BAs in snake bile. In all, 61 snake bile from 17 commonly used species of three families (Elapidae, Colubridae and Viperidae), along with five batches of commercial snake bile from four companies, were collected and detected. Nine components, Tauro-3alpha,12alpha-dihydroxy-7-oxo-5beta-cholenoic acid (T1), Tauro-3alpha,7alpha,12alpha,23R-tetrahydroxy-5beta-cholenoic acid (T2), taurocholic acid (TCA), glycocholic acid (GCA), Taurochenodeoxycholic Acid (TCDCA), taurodeoxycholic acid (TDCA), cholic acid (CA), Tauro-3alpha,7alpha-dihydroxy-12-oxo-5beta-cholenoic acid (T3), and Tauro-3alpha,7alpha,9alpha,16alpha-tetrahydroxy-5beta-cholenoic acid (T4) were simultaneously and rapidly determined for the first time. In these BAs, T1 and T2, self-prepared with purity above 90%, were first reported with their quantitative determination, and the latter two (T3 and T4) were tentatively determined by quantitative analysis multi-components by single marker (QAMS) method for roughly estimating the components without reference. The developed method was validated with acceptable linearity (r(2)>/=0.995), precision (RSD6.5%) and recovery (RSD7.5%). It turned out that the contents of BAs among different species were also significantly different; T1 was one of the principle bile acids in some common snake bile, and also was the characteristic one in Viperidae and Elapidae; T2 was the dominant components in Enhydris chinensis. This quantitative study of BAs in snake bile is a remarkable improvement for clarifying the bile acid compositions and evaluating the quality of snake bile.
Bile acid patterns in commercially available oxgall powders used for the evaluation of the bile tolerance ability of potential probiotics.[Pubmed:29494656]
PLoS One. 2018 Mar 1;13(3):e0192964.
This study aimed to analyze the bile acid patterns in commercially available oxgall powders used for evaluation of the bile tolerance ability of probiotic bacteria. Qxgall powders purchased from Sigma-Aldrich, Oxoid and BD Difco were dissolved in distilled water, and analyzed. Conjugated bile acids were profiled by ion-pair high-performance liquid chromatography (HPLC), free bile acids were detected as their p-bromophenacyl ester derivatives using reversed-phase HPLC after extraction with acetic ether, and total bile acids were analyzed by enzymatic-colorimetric assay. The results showed that 9 individual bile acids (i.e., taurocholic acid, glycocholic acid, taurodeoxycholic acid, glycodeoxycholic acid, Taurochenodeoxycholic Acid, glycochenodeoxycholic acid, cholic acid, chenodeoxycholic acid, deoxycholic acid) were present in each of the oxgall powders tested. The content of total bile acid among the three oxgall powders was similar; however, the relative contents of the individual bile acids among these oxgall powders were significantly different (P < 0.001). The oxgall powder from Sigma-Aldrich was closer to human bile in the ratios of glycine-conjugated bile acids to taurine-conjugated bile acids, dihydroxy bile acids to trihydroxy bile acids, and free bile acids to conjugated bile acids than the other powders were. It was concluded that the oxgall powder from Sigma-Aldrich should be used instead of those from Oxoid and BD Difco to evaluate the bile tolerance ability of probiotic bacteria as human bile model.
Effect of a high-fat-high-cholesterol diet on gallbladder bile acid composition and gallbladder motility in dogs.[Pubmed:29182389]
Am J Vet Res. 2017 Dec;78(12):1406-1413.
OBJCTIVE To investigate the effects of dietary lipid overload on bile acid metabolism and gallbladder motility in healthy dogs. ANIMALS 7 healthy Beagles. PROCEDURES In a crossover study, dogs were fed a high-fat-high-cholesterol diet (HFCD) or a low-fat diet (LFD) for a period of 2 weeks. After a 4-month washout period, dogs were fed the other diet for 2 weeks. Before and at the end of each feeding period, the concentrations of each of the gallbladder bile acids, cholecystokinin (CCK)-induced gallbladder motility, and bile acid metabolism-related hepatic gene expression were examined in all dogs. RESULTS The HFCD significantly increased plasma total cholesterol concentrations. The HFCD also increased the concentration of Taurochenodeoxycholic Acid and decreased the concentration of taurocholic acid in bile and reduced gallbladder contractility, whereas the LFD significantly decreased the concentration of taurodeoxycholic acid in bile. Gene expression analysis revealed significant elevation of cholesterol 7alpha-hydroxylase mRNA expression after feeding the HFCD for 2 weeks, but the expression of other genes was unchanged. CONCLUSIONS AND CLINICAL RELEVANCE Feeding the HFCD and LFD for 2 weeks induced changes in gallbladder bile acid composition and gallbladder motility in dogs. In particular, feeding the HFCD caused an increase in plasma total cholesterol concentration, an increase of hydrophobic bile acid concentration in bile, and a decrease in gallbladder sensitivity to CCK. These results suggested that similar bile acid compositional changes and gallbladder hypomotility might be evident in dogs with hyperlipidemia.
